Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotheraphy
    • Applied and Environmental Mircobiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotheraphy
    • Applied and Environmental Mircobiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
LETTERS TO THE EDITOR

Combination Therapy with Ampicillin and Daptomycin for Treatment of Enterococcus faecalis Endocarditis

M. Sierra-Hoffman, O. Iznaola, M. Goodwin, J. Mohr
M. Sierra-Hoffman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
O. Iznaola
Beeville Medical Associates Beeville, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Goodwin
Optimer Pharmaceuticals San Diego, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Mohr
Cubist Pharmaceuticals, Inc. Lexington, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01760-12
  • Article
  • Info & Metrics
  • PDF
Loading

LETTER

Enterococci are identified as the causative pathogen in approximately 10 percent of infective endocarditis cases, and the most frequently isolated species are Enterococcus faecalis and Enterococcus faecium (3). Gentamicin in combination with penicillins or glycopeptides is recommended for enterococcal endocarditis treatment; however, the incidence of ototoxicity and nephrotoxicity with aminoglycosides is a concern, especially in older patients. Daptomycin is a cyclic lipopeptide with in vitro activity against a variety of Gram-positive pathogens, including Enterococcus spp., exhibiting a unique mechanism of action resulting in rapid bacterial cell death. However, development of resistance in enterococci with daptomycin monotherapy has been reported (1). In vitro combinations of daptomycin and ampicillin have demonstrated a delayed ability to select out strains of Enterococcus with MICs of >4 μg/ml after multiple serial passages (2). Sakoulas and colleagues reported a case of a hemodialysis patient with ampicillin- and vancomycin-resistant E. faecium left-sided endocarditis who failed on a combination of daptomycin (6 mg/kg of body weight every 48 h [q48h]) and linezolid. The patient then received a combination of daptomycin (12 mg/kg q48h) and ampicillin (1 g q6h), with blood cultures clearing within 24 h. Additional studies of this isolate demonstrated that ampicillin reduced the net positive bacterial surface charge for an increased bactericidal effect of daptomycin (4). While the published clinical data on the treatment of enterococcal endocarditis using a combination of daptomycin and ampicillin are scarce, we feel that daptomycin plus ampicillin is a reasonable treatment option for enterococcal endocarditis, have integrated this combination into our treatment armamentarium, and have treated several patients successfully.

We report a case of an 89-year-old Caucasian female in good health but with a history of chronic hypertension and stage 4 chronic kidney disease (estimated baseline glomerular filtration rate [GFR] of 25 ml/min) who was admitted to the hospital after developing fever, generalized weakness, confusion, and an episode of cholelithiasis 2 weeks prior to the current admission. Levofloxacin was started empirically, and blood cultures were obtained. On day 2 of admission, blood cultures grew E. faecalis susceptible to daptomycin (MIC ≤ 4 μg/ml) and ampicillin. A transesophageal echocardiogram revealed a 0.89- by 1.4-cm mitral valve vegetation. Her cardiologist determined she was not a candidate for surgery. An infectious disease consult led to a decision to manage the patient medically. Levofloxacin was discontinued, and ampicillin (1 g q6h) and daptomycin (6 mg/kg q48h) were initiated with a goal of 6 weeks of therapy. Creatine phosphokinase was measured routinely throughout the 6 weeks, with no significant elevation noted. At week 6, blood cultures were negative and antibiotics were stopped, and repeat blood cultures 2 weeks later were also negative. Twelve months later, the patient was alive and had no clinical signs of endocarditis or active infection.

The combination of daptomycin and ampicillin yielded a successful outcome for treating E. faecalis endocarditis in this patient while providing an alternative to daptomycin monotherapy or an aminoglycoside-containing regimen. It has been suggested that doses higher than those approved by the FDA should be used to treat staphylococcal bacteremia; however, as shown here, when using an FDA-approved dose in combination with ampicillin, increased doses may not be necessary. Additional studies are needed to further explore this combination for the treatment of enterococcal endocarditis.

  • Copyright © 2012, American Society for Microbiology. All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Arias CA,
    2. et al
    . 2007. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin. Infect. Dis. 45:1343–1346.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Entenza JM,
    2. Giddey M,
    3. Vouillamoz J,
    4. Moreillon P
    . 2010. In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin. Int. J. Antimicrob. Agents 35:451–456.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Murdoch DR,
    2. et al
    . 2009. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch. Intern. Med. 169:463–473.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Sakoulas G,
    2. et al
    . 2012. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 56:838–844.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Download PDF
Citation Tools
Combination Therapy with Ampicillin and Daptomycin for Treatment of Enterococcus faecalis Endocarditis
M. Sierra-Hoffman, O. Iznaola, M. Goodwin, J. Mohr
Antimicrobial Agents and Chemotherapy Oct 2012, 56 (11) 6064; DOI: 10.1128/AAC.01760-12

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Combination Therapy with Ampicillin and Daptomycin for Treatment of Enterococcus faecalis Endocarditis
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
Share
Combination Therapy with Ampicillin and Daptomycin for Treatment of Enterococcus faecalis Endocarditis
M. Sierra-Hoffman, O. Iznaola, M. Goodwin, J. Mohr
Antimicrobial Agents and Chemotherapy Oct 2012, 56 (11) 6064; DOI: 10.1128/AAC.01760-12
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • LETTER
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

Copyright © 2019 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596